Glonghui May 23 丨 Novartis Health (6606.HK) bucked the trend, rising nearly 8% intraday to HK$28.75. According to Goldman Sachs Research Report, medical equipment is still the bank's preferred sub-industry in the healthcare sector in China, and Novartis Health was added to the list of confident purchases, and the list price was raised 3% from HK$52.7 to HK$54.5. Main reasons: 1) Expected strong performance in the first half of the year; 2) Increased visibility of long-term growth. Goldman Sachs raised its 2023-2025 sales forecast by 5%/3%/7%.
港股异动丨诺辉健康拉升涨近8%，获高盛升目标价至54.5港元
Hong Kong stock changes丨Novartis Health rose nearly 8%, receiving Goldman Sachs's target price increase to HK$54.5
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.